FDA Approves Dupilumab for Bullous Pemphigoid
Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.
Dupilumab (Dupixent), a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, is now approved in the United States for eight diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company's press release.
The approval follows a supplemental New Drug Application filed with the FDA in February 2025 and is based on data from ADEPT, a pivotal phase 2/3 study in more than 100 adults with moderate-to-severe bullous pemphigoid known as, according to Regeneron. The study's design was published in Advances in Therapy.
In the study, 106 patients were randomized to 300 mg of subcutaneous dupilumab or a placebo injection every 2 weeks, added to standard-of-care oral corticosteroids. At 36 weeks, 18.3% of patients in the dupilumab group achieved the primary endpoint of sustained disease remission compared with 6.1% of those in the placebo group. The study defined sustained remission as a combination of complete clinical remission and no relapse after an oral corticosteroid taper by 16 weeks, with no use of rescue therapy during the study period.
More patients treated with dupilumab achieved a clinically meaningful reduction in itching (38.3% vs 10.5%), and the median cumulative oral corticosteroid dose in the dupilumab-treated group was 2.8 g vs 4.1 g in the placebo group, according to the company release.
The most common adverse events among patients receiving dupilumab (affecting 2% or more) compared with those receiving placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis. One patient receiving dupilumab also developed acute generalized exanthematous pustulosis; no cases were reported among those receiving placebo.
The dupilumab study was funded by Sanofi and Regeneron, the companies co-developing dupilumab.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
34 minutes ago
- CBS News
Murkowski says she has been "pretty clear" about her concerns with Trump's "big, beautiful bill"
Republican Sen. Lisa Murkowski says she has been "pretty clear" about her concerns over potential cuts President Trump's so-called "big, beautiful bill" would make to Medicaid and food benefits for her constituents in Alaska. In an interview for "CBS Sunday Morning," Murkowski told CBS News senior correspondent Norah O'Donnell that she hasn't given any absolute deal-breakers in the Senate legislation — but she's voiced her reservations about the Medicaid proposals. "I have not given anybody in the administration an absolute, this is my red line, right?" Because I think it's important that every step of the way, I communicate where my concerns are," Murkowski told O'Donnell in the interview airing this weekend. The reconciliation bill — or "one big, beautiful bill," as Mr. Trump and Republicans in Congress have dubbed it — has passed the House, but remains up for debate in the Senate, where some Republicans are pushing for deeper cuts to Medicaid than the House-passed version allows. Medicaid is the entitlement program that offers government-backed health care for both low-income Americans and those with disabilities, with the federal government and states splitting the costs. While the House version adds a new work requirement to Medicaid for childless adults, the Senate wants work requirements to expand to parents of older children. The Supplemental Nutrition Assistance Program, or SNAP, provides food benefits to the poorest Americans, and some Senate Republicans are hoping to place more requirements on states. "So I've been pretty clear that when it comes to Medicaid, those cuts that would harm Alaskan beneficiaries, that's not something that I can take home, right? We have some of the highest health care costs in the country. We have 40% of Alaska's kids that are on Medicaid. I want to try to do what we can to address certain aspects of our entitlement spending. We've got to do that. But doing it with the most vulnerable bearing the brunt of that is not the answer," she said. Senate Majority Leader John Thune, a Republican from North Dakota, wants the reconciliation bill to pass by the July 4 holiday, but that deadline is quickly approaching. Watch more of the interview with Sen. Lisa Murkowski on "CBS Sunday Morning" on Sunday, June 22.
Android Authority
an hour ago
- Android Authority
Max quietly added 50% more commercials to your stream
Edgar Cervantes / Android Authority TL;DR Streaming providers are adding more commercials, as recently confirmed for Prime Video. It turns out that Max already did the same thing earlier this year. Back in February, Max raised ad loads from 4 minutes an hour to 6 minutes an hour. Inflation sucks, but at least when a company directly raises prices, the impact is transparent. A lot of times, though, the effect is obscured by companies minimizing actual price hikes, and instead just giving us less for our money — you might see this at the grocery store in the form of sizes getting smaller. With streaming media, a company can achieve the same thing by reducing the quality of the service it offers, and one to do that which is a lot more subtle than dropping half your licensed content is just by squeezing in more ads. Last week we heard about Amazon's Prime Video increasing the amount of advertising it showed from 2–3 minutes an hour to 4–6 minutes. We didn't love that, but it turns out Amazon is far from alone here, and PCWorld has uncovered evidence that Max (or soon to once again be HBO Max) has quietly done basically the same thing. Like Netflix and other streamers, Max offers a variety of plan tiers. There's the premium 4K option for $21 a month and the standard 1080p plan at $16, both ad-free. But then there's also an ad-supported basic plan (still at 1080p, at least), available at the reduced rate of $10 a month. If you visit Max's support page for questions about advertisements on the service, today you'll find the company telling customers: If you subscribe to the Basic with Ads plan, ads will play before and during shows and movies (about 6 minutes of ads per hour). But what PCWorld noticed is that this number has gotten a bit higher over the last few months. When the Internet Archive's Wayback Machine visited the page on February 16, Max was singing a different tune: If you subscribe to the Basic with Ads plan, ads will play before and during shows and movies (about 4 minutes of ads per hour). When the site next archived the page on February 28, the current 6-minute language was in place. Max and Amazon are far from alone in increasing the ad load on subscribers, and the practice is more or less standard across the industry. But it's one thing to just get the impression that you're sitting through more ads than you used to, and another when a company clearly communicates what you should expect like this. For that, we have to give Max at least a little credit. Got a tip? Talk to us! Email our staff at Email our staff at news@ . You can stay anonymous or get credit for the info, it's your choice.
Medscape
an hour ago
- Medscape
EMA Recommends Rezdiffra for MASH Liver Fibrosis
The European Medicines Agency (EMA) has recommended conditional marketing authorization for Rezdiffra (resmetirom) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. MASH was formerly known as nonalcoholic fatty liver disease (NASH). There are currently no authorized treatments for MASH in the EU, making Rezdiffra a potential first. MASH is a serious liver disease that occurs when fat accumulates in the liver, causing inflammation. Left untreated, it can lead to cirrhosis and cancer. Symptoms may only present in more advanced stages of the condition, at which point they may include discomfort or pain in the upper right abdomen, muscle weakness or loss, and swelling in the abdomen or legs. Estimates suggest that up to 5% of people in Europe have MASH and that around 25% have metabolic dysfunction‐associated steatotic liver disease (MASLD), the condition that precedes MASH. MASLD was previously known as nonalcoholic fatty liver disease (NAFLD). The active substance of Rezdiffra is resmetirom, which is a partial agonist of the thyroid hormone receptor-beta. It works by promoting lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis. The EMA's decision comes after interim results from a pivotal, ongoing phase 3 trial including 966 adults with biopsy-confirmed MASH with varying stages of fibrosis. Patients were randomly assigned treatment on a 1:1:1 ratio to receive once-daily resmetirom at 80 mg or 100 mg, or a placebo. The primary endpoints were MASH resolution at week 52 with no worsening of fibrosis, and a reduction in fibrosis by at least one stage alongside no worsening of NAFLD activity score. MASH resolution included a reduction in the NAFLD activity score by ≥ 2 points. Scores range from 0 to 8; higher scores indicate more severe disease. After 12 months, 30% of patients in the 100 mg resmetirom group and 26% of those in the 80 mg group achieved MASH resolution with no worsening fibrosis compared with 10% in the placebo group. Meanwhile, 26% of patients in the 100 mg resmetirom group and 24% of patients in the 80 mg group experienced fibrosis improvement by at least one stage with no worsening of NAFLD activity score compared with 14% in the placebo group. The most frequent side effects were diarrhea, nausea, itching, and pruritus. Diarrhea and nausea were more frequent among those taking resmetirom than those taking the placebo. The rate of serious adverse events was similar across all groups and ranged from 10.9% to 12.7%. Rezdiffra will be available as 60 mg, 80 mg, and 100 mg film-coated tablets. It should be taken alongside diet and exercise. The opinion adopted by the EMA will now go to the European Commission to await a decision on EU-wide marketing authorization. In the meantime, the EMA has required Rezdiffra's applicant to complete both the pivotal and another ongoing trial to provide further data regarding the drug's efficacy. This conditional approval comes as the EMA perceives that the benefits to patients from immediate availability outweigh the risk inherent in incomplete data. Detailed recommendations for using Rezdiffra will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages.
